Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
This page is not indexed by search engines while we improve data quality.
Roussy Inst Gustave — Physics
Roussy Inst Gustave holds 64 patents in Physics, with representative filings summarized below.
| Metric | Value |
|---|---|
| Company | Roussy Inst Gustave |
| Technology | Physics |
| Patents in slice | 64 |
| Recent patents in slice | 16 |
| First year | 2015 |
| Last year | 2026 |
Representative patents
Notable publications linking Roussy Inst Gustave to Physics.
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Recent filings
Latest patents from Roussy Inst Gustave in Physics.
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Radiomics-based imaging tool to monitor tumor-lymphocyte infiltration and outcome in cancer patients treated by anti-PD-1/PD-L1
US-12590949-B2 · Mar 31, 2026 · US
Related pages
Navigate to parent entity pages.